New Lundbeck candidate to kick off R&D division

With the acquisition of the biotherapy candidate from South Korean Aprilbio, Lundbeck has obtained the first development program within a new strategic focus area, neuroimmunology. Lundbeck's EVP and research lead is keeping his cards close about potential drug indications.
Photo: PR / Lundbeck
Photo: PR / Lundbeck

Since Lundbeck went through a larger shift in its research and development division, the company has been busy scouting for assets that could fit in its new focus area, neuroinflammation or neuroimmunology.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading